Clinical reports have demonstrated that the lower response to CLOP therapy in CAD patients with DM is attributed to the low exposure of CLOP-AM, which may be associated with the altered activities of some hepatic enzymes in DM status (Yang and Liu, 2020), such CYP2C19 and CES1. This evidence concerns the gene CES1 and coronary artery disorder.